Acetaldehyde Activated Charcoal Arsenic Trioxide C
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Acetaldehyde Activated Charcoal Arsenic Trioxide C
- Multi-Component Preparation (14 Ingredients): Evaluation Not Possible — Insufficient Evidence
Multi-Component Preparation (14 Ingredients): Evaluation Not Possible — Insufficient Evidence
One-Sentence Summary
This entry represents a complex mixture of 14 chemically diverse components including Arsenic Trioxide, Epinephrine, Activated Charcoal, and Silver Nitrate, with no established original indication on record. The TxGNN pipeline returned no predicted indications for this compound group, and no supporting clinical trials or publications were identified. Evaluation cannot proceed without first resolving fundamental data gaps at the drug identity level.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no regulatory approvals on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 (no prediction, no studies) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No TxGNN prediction was generated for this entry, making a mechanism-based repurposing rationale impossible to construct at this stage.
The queried drug string is a semicolon-delimited list of 14 structurally unrelated substances: Acetaldehyde, Activated Charcoal, Arsenic Trioxide, Coumarin, Deoxymutaaspergillic Acid, Epinephrine, Gallic Acid Monohydrate, Histamine Dihydrochloride, Hydrangea Arborescens Root, Indole-3-Carbinol, Liquid Petroleum, Rutin, Silver Nitrate, and Yeast Mannan. This string was submitted as a single query entity, which likely caused the pipeline to fail to map the entry to any node in the TxGNN knowledge graph — resulting in zero predictions.
It is worth noting that several individual components (e.g., Arsenic Trioxide for acute promyelocytic leukaemia, Epinephrine for anaphylaxis) do have established clinical uses when evaluated independently. The failure here is a data ingestion issue, not necessarily a pharmacological dead end.
Safety Considerations
Please refer to the package insert for safety information.
Special note on Arsenic Trioxide: As an individual component, Arsenic Trioxide (DB01169) carries well-documented black box warnings including QT prolongation, differentiation syndrome, and haematological toxicity. If this compound is re-queried as a standalone drug, its safety profile must be fully evaluated before any repurposing decision.
Conclusion and Next Steps
Decision: Hold
Rationale: The pipeline received a concatenated multi-ingredient string and could not resolve it to a single drug entity in the TxGNN knowledge graph, producing zero predictions and zero evidence. No evaluation is possible in this state.
To proceed, the following is needed:
- Clarify drug identity: Determine whether this is a single formulated product (e.g., a compounded preparation or diagnostic reagent) or a data entry error (e.g., multiple drugs merged into one row)
- Re-query each component individually: Submit each of the 14 ingredients as a separate TxGNN query to obtain individual repurposing predictions
- Obtain DrugBank IDs: At minimum for pharmacologically active components (Arsenic Trioxide, Epinephrine, Rutin, Coumarin, Indole-3-Carbinol) to enable MOA-based analysis
- Identify the product’s original indication: Search TFDA, FDA Orange Book, or manufacturer labelling for the combination product’s intended therapeutic use
- Resolve the INN string format: The current INN field contains a query-unfriendly semicolon-delimited list; standardise to a single primary active ingredient before re-running the pipeline
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.